biblioteca virtual en salud

Búsqueda | Gripe por A(H1N1)

  • BIREME | OPAS | OMS logo

Historico de búsqueda  ()

Su selección  ()

 0 documento(s) seleccionado(s).

Refine su búsqueda

Collapse All  Ocultar
Expand All  Mostrar
Áreas temáticas
Texto completo (5026)

Enviar por email

Ud. tiene 0 documento(s) seleccionado(s).

Ningún documento seleccionado

Resultados  1-12 de 7.108

Respuesta inmune humoral inducida por la vacuna influenza en niños con diagnóstico de leucemia linfoblástica aguda/ Humoral immune response induced by influenza vaccine in children with acute lymphoblastic leukemia

Autor(es): Cerda, Carolina; Martínez-Valdebenito, Constanza; Barriga, Francisco; Contreras, Marcela; Vidal, Marcela; Moreno, Rosa; Claverie, Ximena; Contreras, Paola; Huenuman, Lesly; García, Tamara; Rathnasighe, Raveen; Medina, Rafael; Ferrés, Marcela; Le Corre, Nicole
Fuente: Rev. chil. infectol;37(2): 138-146, abr. 2020. tab, graf
LILACS - Literatura Latinoamericana y del Caribe en Ciencias de la Salud ID: 1126100
Resumen: Resumen Introducción: Los pacientes con leucemia linfoblástica aguda (LLA) tienen alto riesgo de influenza grave y la vacunación es altamente recomendada. La inmunogenicidad y efectividad de la vacuna es menor comparada a los sujetos sanos. Objetivo: Evaluar la respuesta inmune inducida por vacuna anti-influenza en niños con LLA y observar su efectividad. Métodos: Se reclutaron niños con LLA en terapia de mantención y niños sanos. Se tomaron muestras de sangre el día de la vacun (mas)

Influenza vaccine effectiveness estimates against influenza A(H3N2) and A(H1N1) pdm09 among children during school-based outbreaks in the 2016-2017 season in Beijing, China.

Autor(es): Zhang, Li; van der Hoek, Wim; Krafft, Thomas; Pilot, Eva; Asten, Liselotte van; Lin, Ge; Wu, Shuangsheng; Duan, Wei; Yang, Peng; Wang, Quanyi
Fuente: Hum Vaccin Immunother;16(4): 816-822, 2020 Apr 02.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 31596661
Resumen: Background: Since 2007, trivalent inactivated influenza vaccine (TIV) has been provided free-of-charge to primary, middle school and high school students in Beijing. However, there have been few school-based studies on influenza vaccine effectiveness (VE). In this report, we estimated influenza VE against laboratory-confirmed influenza illness among school children in Beijing, China during the 2016-2017 influenza season.Methods: The VE of 2016-2017 TIV against laboratory-confirmed influenza (mas)

Factors associated with adverse outcomes during influenza outbreaks in aged care facilities.

Autor(es): Tennant, Elaine; Fletcher, Stephanie; Kakar, Sheena; Najjar, Zeina; Lord, Heidi; Clark, Penelope; Gupta, Leena
Fuente: Aust N Z J Public Health;44(1): 65-72, 2020 Feb.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 31617654
Resumen: OBJECTIVE: To explore factors associated with adverse outcomes during influenza outbreaks in residential aged care facilities. METHODS: A retrospective cohort study of all outbreaks reported to three Sydney metropolitan Public Health Units during 2017. RESULTS: A total of 123 outbreaks affected 1,787 residents and 543 staff. Early notification to a Public Health Unit was associated with shorter outbreak duration (p<0.001; B=0.674). Resident attack rates and resident mortality rates were low (mas)

Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection.

Autor(es): Mandon, Elodie Desuzinges; Pizzorno, Andrés; Traversier, Aurélien; Champagne, Anne; Hamelin, Marie Eve; Lina, Bruno; Boivin, Guy; Dejean, Emmanuel; Rosa-Calatrava, Manuel; Jawhari, Anass
Fuente: Vaccine;38(2): 278-287, 2020 Jan 10.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 31630939
Resumen: Influenza A viruses cause major morbidity and represent a severe global health problem. Current influenza vaccines are mainly egg-based products requiring the split of whole viruses using classical detergents such as Triton X-100, which implies certain limitations. Here, we report the use of the novel calixarene-based surfactant CALX133ACE as an alternative to classical detergents for influenza inactivated split vaccine preparation. We confirmed that CALX133ACE-based split HA antigens are f (mas)

Effectiveness of influenza vaccine in children in preventing influenza associated hospitalisation, 2018/19, England.

Autor(es): Pebody, R G; Zhao, H; Whitaker, H J; Ellis, J; Donati, M; Zambon, M; Andrews, N
Fuente: Vaccine;38(2): 158-164, 2020 Jan 10.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 31648914
Resumen: 2013/14 saw the start of the introduction of a new live attenuated influenza vaccine (LAIV) programme for children in England. 2018/19 saw co-circulation of both A(H1N1)pdm09 and A(H3N2), when LAIV was offered to all healthy children 2-9 years of age. LAIV effectiveness against influenza hospitalisation is not well described. This paper presents the 2018/19 end-of-season adjusted vaccine effectiveness (aVE) against laboratory confirmed influenza related hospitalisation in children aged (mas)

Protection provided by influenza vaccine against influenza-related hospitalisation in ≥65 year olds: Early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19.

Autor(es): Pebody, Richard; Whitaker, Heather; Zhao, Hongxin; Andrews, Nick; Ellis, Joanna; Donati, Matthew; Zambon, Maria
Fuente: Vaccine;38(2): 173-179, 2020 Jan 10.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 31653528
Resumen: 2018/19 was the first season of introduction in England of a newly licensed adjuvanted influenza vaccine (aTIV) for adults 65 years or older, who were previously offered standard-dose, non-adjuvanted vaccine, achieving uptake levels >70%, often with poor effectiveness. This paper presents the end-of-season adjusted vaccine effectiveness (aVE) against laboratory confirmed influenza hospitalisation in this population. A frequency-matched test negative case control approach was used to es (mas)

Immunogenicity of the inactivated influenza vaccine in children who have undergone allogeneic haematopoietic stem cell transplant.

Autor(es): Ryan, Anne L; Wadia, Ushma D; Jacoby, Peter; Cheung, Laurence C; Kerr, Fiona; Fraser, Chris; Tapp, Heather; Mechinaud, Francoise; Carolan, Louise A; Laurie, Karen L; Barr, Ian G; Blyth, Christopher C; Gottardo, Nicholas G; Richmond, Peter C; Kotecha, Rishi S
Fuente: Bone Marrow Transplant;55(4): 773-779, 2020 Apr.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 31659236
Resumen: Influenza vaccination is recommended for children following allogeneic haematopoietic stem cell transplant (HSCT), however there is limited evidence regarding its benefit. A prospective multicentre study was conducted to evaluate the immunogenicity of the inactivated influenza vaccine in children who have undergone HSCT compared with healthy age-matched controls. Participants were vaccinated between 2013 and 2016 according to Australian guidelines. Influenza-specific hemagglutinin inhibitio (mas)

Biosafety risk assessment for production of candidate vaccine viruses to protect humans from zoonotic highly pathogenic avian influenza viruses.

Autor(es): Chen, Li-Mei; Donis, Ruben O; Suarez, David L; Wentworth, David E; Webby, Richard; Engelhardt, Othmar G; Swayne, David E
Fuente: Influenza Other Respir Viruses;14(2): 215-225, 2020 03.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 31659871
Resumen: A major lesson learned from the public health response to the 2009 H1N1 pandemic was the need to shorten the vaccine delivery timeline to achieve the best pandemic mitigation results. A gap analysis of previous pre-pandemic vaccine development activities identified possible changes in the Select Agent exclusion process that would maintain safety and shorten the timeline to develop candidate vaccine viruses (CVVs) for use in pandemic vaccine manufacture. Here, we review the biosafety charact (mas)
Resultados  1-12 de 7.108